PMC:7344504 / 13439-13609 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"354","span":{"begin":115,"end":123},"obj":"Species"},{"id":"357","span":{"begin":31,"end":44},"obj":"Chemical"},{"id":"358","span":{"begin":54,"end":64},"obj":"Chemical"}],"attributes":[{"id":"A354","pred":"tao:has_database_id","subj":"354","obj":"Tax:9606"},{"id":"A357","pred":"tao:has_database_id","subj":"357","obj":"MESH:C012990"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"city in BAL fluids compared to galactomannan [36] and β-d-glucan [37] in IPA-probable and proven immunocompromised patients. In the ICU setting, however, LFD is suggested"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T98","span":{"begin":46,"end":48},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"}],"text":"city in BAL fluids compared to galactomannan [36] and β-d-glucan [37] in IPA-probable and proven immunocompromised patients. In the ICU setting, however, LFD is suggested"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T105","span":{"begin":8,"end":11},"obj":"Chemical"},{"id":"T106","span":{"begin":31,"end":44},"obj":"Chemical"},{"id":"T107","span":{"begin":58,"end":64},"obj":"Chemical"},{"id":"T108","span":{"begin":73,"end":76},"obj":"Chemical"},{"id":"T110","span":{"begin":154,"end":157},"obj":"Chemical"}],"attributes":[{"id":"A105","pred":"chebi_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/CHEBI_64198"},{"id":"A106","pred":"chebi_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A107","pred":"chebi_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/CHEBI_37163"},{"id":"A108","pred":"chebi_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A109","pred":"chebi_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_73571"}],"text":"city in BAL fluids compared to galactomannan [36] and β-d-glucan [37] in IPA-probable and proven immunocompromised patients. In the ICU setting, however, LFD is suggested"}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T6","span":{"begin":31,"end":44},"obj":"GlycoEpitope"}],"attributes":[{"id":"A6","pred":"glyco_epitope_db_id","subj":"T6","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"city in BAL fluids compared to galactomannan [36] and β-d-glucan [37] in IPA-probable and proven immunocompromised patients. In the ICU setting, however, LFD is suggested"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T21","span":{"begin":73,"end":76},"obj":"Phenotype"}],"attributes":[{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"city in BAL fluids compared to galactomannan [36] and β-d-glucan [37] in IPA-probable and proven immunocompromised patients. In the ICU setting, however, LFD is suggested"}

{"project":"2_test","denotations":[{"id":"32517166-25903568-60114412","span":{"begin":46,"end":48},"obj":"25903568"},{"id":"32517166-24671798-60114413","span":{"begin":66,"end":68},"obj":"24671798"}],"text":"city in BAL fluids compared to galactomannan [36] and β-d-glucan [37] in IPA-probable and proven immunocompromised patients. In the ICU setting, however, LFD is suggested"}